I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Myopic Degeneration: Protecting Your Vision and Your Retinal Health
What Is Myopic Degeneration
Myopic degeneration goes beyond ordinary nearsightedness. It involves physical changes to the structure of the eye that can lead to lasting vision problems if left unmonitored or untreated.
Nearsightedness, also called myopia, means the eye focuses light in front of the retina rather than directly on it, making distant objects appear blurry. For most people, glasses or contact lenses fully correct this. High myopia is generally defined as a prescription stronger than negative 6.00 diopters or an eye length greater than 26 millimeters. At this level, the eye has grown significantly longer from front to back than a typical eye.
Myopic degeneration refers to the structural damage that can result from that extra length. Not everyone with high myopia develops it, but the risk increases with greater eye length and advancing age.
As the eye grows longer, it does not produce new tissue to cover the larger surface area. Instead, the existing layers of the eye stretch and thin. This includes the retina (the light-sensitive tissue lining the back of the eye) and the retinal pigment epithelium (RPE), a supportive layer directly beneath the retina. When the RPE breaks down, a retina specialist examining the eye may be able to see the underlying blood vessel layer (the choroid) or even the white outer wall of the eye (the sclera) through the thinned tissue.
Several serious problems can arise as the eye's tissues stretch and thin further over time. Cracks in the supportive membrane beneath the retina, called lacquer cracks, may form. Areas of RPE loss, called atrophy, can appear and slowly expand. The retina itself can develop holes or tears. The vitreous (the clear gel that fills the inside of the eye) may also pull away from the retina, which can create additional risk.
One of the most serious complications is choroidal neovascularization (CNV), the growth of abnormal new blood vessels beneath the retina. These fragile vessels can leak fluid or blood, causing rapid and significant damage to central vision. CNV requires prompt treatment when it develops.
Who Is Affected and What Increases Risk
Myopic degeneration is more common than many people realize, and certain factors make some individuals more vulnerable. Understanding your personal risk profile helps guide how often you should be monitored by a retina specialist.
Nearsightedness has become significantly more common over recent decades, affecting roughly four in ten Americans. High myopia affects a smaller but still meaningful portion of the population. Among people with high myopia, a substantial number will develop some form of myopic macular degeneration over their lifetime. The condition is recognized as one of the leading causes of vision loss in the United States, Europe, and parts of Asia, which underscores the importance of regular monitoring.
Several factors raise the likelihood of developing myopic degeneration. Having a longer eye from front to back is the most direct risk factor. Other important factors include:
- A stronger nearsighted prescription, particularly beyond negative 6.00 diopters
- Older age, although degenerative changes have been seen in people as young as their twenties
- A family history of high myopia or myopic degeneration
- East or Southeast Asian ancestry, where rates of high myopia are the highest documented globally
If any of these factors apply to you, regular evaluations with a retina specialist are especially important.
Myopic degeneration can affect both eyes, though it may not progress at the same rate in each. Research shows that a significant portion of patients who develop abnormal blood vessel growth in one eye will develop it in the other eye within several years. This is why our team monitors both eyes closely at every visit, even when only one eye currently shows signs of the condition.
Recognizing the Signs and Symptoms
Myopic degeneration often progresses silently in its early stages, making routine check-ups essential. Knowing what symptoms to watch for can help you seek care at the right moment and protect your vision.
In the early stages, myopic degeneration often causes no symptoms at all. The stretching and thinning of retinal tissue can be detected during a dilated eye exam before any vision changes occur. This is why regular retinal examinations are so important for anyone with high myopia, even when vision seems perfectly stable.
As the condition advances, some people notice a gradual decline in their best-corrected vision, meaning their vision worsens even with the correct glasses or contact lens prescription. Colors may seem slightly faded, and fine details may become harder to distinguish.
When CNV develops, symptoms often appear quickly rather than building slowly. Central vision may drop noticeably over days or even weeks. Straight lines may appear wavy or bent, a symptom called metamorphopsia. A dark or gray patch may appear in the center of the visual field. These central blind spots are called scotomas and can significantly affect daily activities like reading, driving, and recognizing faces.
Color perception may also change noticeably. Any of these symptoms in a person with high myopia should prompt an urgent evaluation by a retina specialist rather than a wait-and-see approach.
Certain warning signs should never be ignored or delayed. If you have high myopia and experience any of the following, contact a retina specialist immediately or go to the nearest emergency room:
- Sudden loss of vision in one eye
- Straight lines that suddenly appear wavy, bent, or distorted
- A new dark or gray spot in the center of your vision
- A sudden increase in floaters or new flashes of light
- A curtain or shadow spreading across part of your visual field
These symptoms may signal active CNV, a retinal tear, or a retinal detachment. Prompt evaluation and treatment can make a significant difference in the outcome.
How Myopic Degeneration Is Diagnosed
Accurate diagnosis involves a careful eye examination combined with advanced retinal imaging. Our team uses several tools to get a complete picture of your retinal health and guide the best course of action.
Evaluation begins with a comprehensive dilated fundus examination. A retina specialist will measure your glasses prescription and may also assess the physical length of your eye using optical or ultrasound-based techniques. With the pupil fully dilated, the specialist can view the retina and surrounding structures directly, looking for signs of stretching, thinning, atrophy, lacquer cracks, and abnormal blood vessels.
Optical coherence tomography (OCT) is a noninvasive imaging test that produces detailed cross-sectional images of the retina. Think of it as a high-resolution scan of the back of the eye using light rather than sound. OCT can detect fluid beneath the retina, changes in retinal layer thickness, and early signs of CNV that may not yet be visible during a routine examination. Our team uses OCT at each visit to track changes over time and guide treatment decisions.
When CNV is suspected, a retina specialist may recommend fluorescein angiography. During this test, a yellow dye is injected into a vein in the arm. As the dye circulates through the blood vessels of the eye, a specialized camera captures images that clearly reveal leaking or abnormal vessels. Indocyanine green angiography (ICG) uses a different dye and provides additional detail about deeper vessel layers beneath the retina. OCT angiography is another approach that creates detailed images of retinal blood flow without a dye injection. Together, these tools allow for precise diagnosis and treatment planning.
Treatment Options for Myopic Degeneration
Treatment focuses primarily on managing complications, with the most urgent goal being the control of abnormal blood vessel growth to preserve central vision. The right approach depends on the type of complication present and the extent of existing retinal damage.
The primary treatment for myopic CNV is anti-VEGF therapy. VEGF stands for vascular endothelial growth factor, a protein that signals the body to form new blood vessels. In myopic degeneration, this process creates fragile, leaking vessels that damage the retina. Anti-VEGF medications block this signal and help stop vessel growth and leakage. They are delivered through intravitreal injections, which are small injections given directly into the eye in a clinical setting.
Several anti-VEGF medications are used for myopic CNV. Ranibizumab (Lucentis) is FDA-approved specifically for this indication. Aflibercept (Eylea) is also approved for myopic CNV. Bevacizumab (Avastin), which is FDA-approved for cancer treatment, is sometimes used off-label in this setting as well. Anti-VEGF therapy is considered the most effective treatment currently available for myopic CNV, and many patients respond well, often requiring fewer total injections compared to other retinal conditions that involve abnormal vessel growth.
A common approach begins with an initial injection followed by close monthly monitoring. Monitoring includes visual acuity testing and OCT imaging. Additional injections are given only when signs of active disease return, such as new fluid beneath the retina or a measurable drop in vision. This type of schedule is sometimes called a treat-and-monitor or as-needed approach.
Regular follow-up remains essential even during quiet periods when no active disease is present. Our team reviews vision measurements and imaging results at every visit to determine whether retreatment is warranted.
Biosimilars are medications that have been shown to be highly similar to an already-approved biologic drug, manufactured by a different company. The FDA has approved biosimilar versions of both ranibizumab and aflibercept for the treatment of myopic CNV. These options expand access to proven anti-VEGF treatment and provide additional choices for patients and their retina specialists when selecting a medication.
Not all complications of myopic degeneration involve abnormal blood vessel growth. Retinal tears or detachments require prompt surgical attention. Depending on the situation, a retina specialist may recommend vitrectomy (a procedure to remove the vitreous gel inside the eye and repair the retina), laser photocoagulation (a thermal laser used to seal retinal tears), or cryopexy (a freezing treatment applied from outside the eye to seal tears). Macular holes, another complication that can develop with advanced myopic degeneration, may also require vitrectomy. Our team will recommend the most appropriate approach based on each patient's specific situation and the findings on imaging.
What to Expect During and After Treatment
Understanding what a treatment visit involves can ease anxiety and help you prepare. Most patients find intravitreal injections more manageable than they expected going in.
Intravitreal injections are performed in a clinical setting and take only a few minutes from start to finish. Anesthetic drops are applied to numb the surface of the eye before the procedure. Most patients describe a feeling of gentle pressure rather than sharp pain. Some mild redness, a gritty sensation, and temporary blurring of vision are common in the hours after the injection. These effects typically resolve within a day or two.
Serious complications from intravitreal injections are uncommon but can include infection inside the eye (endophthalmitis), bleeding, and retinal detachment. Our team will thoroughly explain the risks and benefits before any procedure and provide clear post-injection care instructions.
Many patients with myopic CNV experience stabilization or noticeable improvement in central vision after anti-VEGF treatment. The response to the first injection is often apparent within weeks. The degree of visual recovery depends on how long CNV was present before treatment began and how much retinal damage had already occurred. Acting promptly when symptoms first appear gives the best chance of preserving vision.
It is important to understand that anti-VEGF therapy addresses the CNV directly but does not reverse the underlying stretching and thinning of the eye's tissues. Ongoing monitoring remains essential to catch any recurrence or new complications early.
Myopic degeneration is a lifelong condition. The structural changes that have occurred in the eye do not resolve on their own, and some degree of gradual change is expected over time. With regular monitoring and timely treatment of complications, many patients maintain useful vision for years and decades. Continued advances in anti-VEGF therapy and the growing availability of biosimilar medications are improving the long-term outlook for people living with this condition.
Living Well with Myopic Degeneration
An active role in your own care makes a real difference. There are practical steps you can take every day to protect your vision and respond quickly if anything changes.
One of the most helpful tools for daily self-monitoring is the Amsler grid, a simple chart printed with a grid of straight lines and a central dot. Looking at the chart with one eye at a time can help you detect new waviness, distortion, or dark areas in your central vision between appointments. If you notice any changes, contact your retina specialist right away rather than waiting for your next scheduled visit.
Wearing your prescribed corrective lenses and protecting your eyes with appropriate safety eyewear during sports or physical activities are also worthwhile steps. UV-blocking sunglasses may offer additional protection for the retina when you are spending time outdoors.
If myopic degeneration has already affected your central vision, low vision rehabilitation services can help you make the most of your remaining sight. These services may include magnifying devices, specialized lighting, large-print materials, and practical training for daily tasks such as reading, cooking, and managing finances. Many people with moderate central vision loss from myopic degeneration continue to live independently and stay socially active.
Because high myopia has a genetic component, close relatives of people with myopic degeneration may face elevated risk. Parents with high myopia should be aware that their children may also be affected. Early identification of high myopia in children allows for closer monitoring as they grow. Timely referral to a retina specialist is important if signs of degenerative change begin to appear at any age.
Frequently Asked Questions
The following answers address specific questions we hear often from patients with myopic degeneration. They are designed to add practical context and decision guidance beyond what has already been covered above.
There is currently no proven way to prevent myopic degeneration once high myopia has developed. The elongation of the eye is not reversible. What can be influenced is how quickly complications are identified and treated. Regular retinal examinations give our team the ability to detect CNV or other changes at their earliest, most treatable stage. Research into slowing eye growth in children is ongoing, and some interventions including specialized eye drops and contact lens designs may help reduce the rate of elongation in younger patients who have not yet reached the threshold of high myopia.
Both conditions involve abnormal blood vessel growth beneath the retina and are treated with anti-VEGF injections, but they differ in important ways. Myopic CNV typically affects younger patients and arises directly from the mechanical stretching and thinning of the eye. Wet age-related macular degeneration (AMD) is primarily a disease of aging and involves a different set of structural changes, including the buildup of deposits called drusen. Myopic CNV often responds more quickly to treatment and usually requires fewer injections over time, which is an important practical distinction when thinking about your treatment plan.
Many patients with myopic CNV need only a limited course of injections, especially compared to conditions like wet AMD. Because myopic CNV typically responds well to initial treatment, recurrences are less frequent. That said, some patients do experience a return of CNV months or even years after initial treatment and may need additional injections at that point. Your retina specialist will monitor for recurrence at regular follow-up visits and recommend further treatment only when signs of active disease are confirmed. The overall treatment burden tends to be lower than many patients expect when they first receive a CNV diagnosis.
No. LASIK and other refractive surgeries reshape the cornea, the clear front surface of the eye, to reduce or eliminate the focusing error of nearsightedness. These procedures do not change the physical length of the eye and have no effect on the stretching or thinning of retinal tissue. A person who has had LASIK still has an elongated eye and remains at the same risk for myopic degeneration and its complications as before the surgery. If you have a history of high myopia and have had refractive surgery, regular retinal monitoring by a retina specialist remains just as important as it would be for someone who has not undergone that procedure.
No lifestyle change has been shown to slow the structural progression of myopic degeneration itself. However, several habits support general retinal health. Monitoring your central vision daily with an Amsler grid is the most direct action you can take to catch new symptoms before they worsen. A diet that includes leafy green vegetables and foods rich in omega-3 fatty acids, along with avoiding smoking, is broadly recommended for retinal health. Wearing UV-protective sunglasses outdoors may offer some additional benefit. Above all, keeping every scheduled appointment with your retina specialist remains the most meaningful step you can take to protect your vision over the long term.
Schedule a Retinal Evaluation with Our Team
If you have high myopia, have been referred for retinal evaluation, or are experiencing any of the symptoms described on this page, we encourage you to schedule a visit at one of our Connecticut offices. At New England Retina Associates, our fellowship-trained vitreoretinal surgeons bring deep expertise, advanced diagnostic technology, and a patient-centered approach to every appointment. We are here to help you understand your condition, protect your vision, and make confident decisions about your care.
30 Years of Care & Commitment
